1. Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia JAMA. 2009;301(4):393-403. doi:10.1001/jama.2009.7 A total of 588 920 germline SNPs were studied in the 371 patients from St Jude and the 227 patients from COG. After quality control filters, 476 796 SNPs in 318 St Jude patients and 169 COG patients were included in the final analysis. ALL indicates acute lymphoblastic leukemia; SNP, single-nucleotide polymorphism. Figure Legend:

2. Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia JAMA. 2009;301(4):393-403. doi:10.1001/jama.2009.7 P values (shown as −log 10 ) for the association of single-nucleotide polymorphism genotypes and minimal residual disease status at the end of induction therapy were calculated by pooling the results from the St Jude and Children's Oncology Group (COG) minimal residual disease cohorts (details in the Supplemental Methods) and plotted from chromosomes 1 to X. Colors discriminate chromosomes. Figure Legend:

3. Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia JAMA. 2009;301(4):393-403. doi:10.1001/jama.2009.7 Single nucleotide polymorphisms (SNPs) in the interleukin 15 (IL15) region plotted with their P values (shown as –log 10 ) from the correlation between genotype and minimal residual disease (MRD) combining the St Jude and Children's Oncology Group cohorts. The 5 IL15 SNPs discussed in the text are shown in red. The arrow indicates the location and transcription direction of the IL15 gene. Figure Legend:

4. Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia JAMA. 2009;301(4):393-403. doi:10.1001/jama.2009.7 COG indicates Children's Oncology Group; MRD, minimal residual disease; SNP, single-nucleotide polymorphism. P values indicate associations between SNP genotypes and MRD, as described in the “Methods” section of the text. Figure Legend:

5. Date of download: 7/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia JAMA. 2009;301(4):393-403. doi:10.1001/jama.2009.7 The cumulative incidence of hematologic relapse was compared by the Gray test (stratified for treatment arms) for each genotype at rs1486649 in the St Jude and Children's Oncology Group (COG) cohorts. This particular single-nucleotide polymorphism (SNP) is intergenic and was chosen because of a reasonable minor allele frequency and low P value (P =.0215 in St Jude; P =.0137 in COG). The risk of relapse at 5 years was 0.055 (95% confidence interval [CI], 0.028-0.081), 0.114 (95% CI, 0.032-0.197), and 0.153 (95% CI, 0-0.358) for patients with AA, AC, and CC genotypes, respectively, in the St Jude cohort. Relapse risk at 5 years among COG patients was 0.216 (95% CI, 0.111-0.321), 0.370 (95% CI, 0.054-0.687), and 0.762 (95% CI, 0.226-1.0) for the AA, AC, and CC genotypes. Difference in scales indicated in blue. Figure Legend: